Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Eddie Thara

Hematology Oncology
Providence
8135 Painter Avenue, Suite 103, 
Downey, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Providence
8135 Painter Avenue, Suite 103, 
Downey, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eddie Thara is a Hematologist Oncology provider in Downey, California. Dr. Thara is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Thrombocytopenia, Congenital Antithrombin 3 Deficiency, Protein S Deficiency, Protein C Deficiency, and Pancreatectomy. Dr. Thara is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Memorialcare Long Beach Medical Center
Memorialcare Orange Coast Medical Center
College Medical Center
Uci Health-Lakewood
St Mary Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

8135 Painter Avenue, Suite 103, Downey, CA 90602
Call: 562-698-6888

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Docetaxel+Plinabulin, Docetaxel
Study Phase: Phase 3
View 5 Less Clinical Trials

8 Total Publications

Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 14, 2021
View All 8 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (21.8 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Robert Figlin is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Figlin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (14.8 miles away)
714-456-7004
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nataliya Mar is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Mar has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, Uci Dept Of Medicine, 
Orange, CA 
 (14.8 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Rezazadeh-Kalebasty is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Rezazadeh-Kalebasty is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thara's expertise for a condition
ConditionClose
      • Advanced
      • Anemia
        Dr. Thara is
        Advanced
        . Learn about Anemia.
        See more Anemia experts
      • Congenital Antithrombin 3 Deficiency
        Dr. Thara is
        Advanced
        . Learn about Congenital Antithrombin 3 Deficiency.
        See more Congenital Antithrombin 3 Deficiency experts
      • Deep Vein Thrombosis
        Dr. Thara is
        Advanced
        . Learn about Deep Vein Thrombosis.
        See more Deep Vein Thrombosis experts
      • Hereditary Resistance to Anti-Vitamin K
        Dr. Thara is
        Advanced
        . Learn about Hereditary Resistance to Anti-Vitamin K.
        See more Hereditary Resistance to Anti-Vitamin K experts
      • Lung Cancer
        Dr. Thara is
        Advanced
        . Learn about Lung Cancer.
        See more Lung Cancer experts
      • Lynch Syndrome
        Dr. Thara is
        Advanced
        . Learn about Lynch Syndrome.
        See more Lynch Syndrome experts
      View All 10 Advanced Conditions
      • Experienced
      • Acute Mountain Sickness
        Dr. Thara is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Acute Myeloblastic Leukemia with Maturation
        Dr. Thara is
        Experienced
        . Learn about Acute Myeloblastic Leukemia with Maturation.
        See more Acute Myeloblastic Leukemia with Maturation experts
      • Acute Myeloblastic Leukemia without Maturation
        Dr. Thara is
        Experienced
        . Learn about Acute Myeloblastic Leukemia without Maturation.
        See more Acute Myeloblastic Leukemia without Maturation experts
      • Acute Myeloid Leukemia (AML)
        Dr. Thara is
        Experienced
        . Learn about Acute Myeloid Leukemia (AML).
        See more Acute Myeloid Leukemia (AML) experts
      • Adult Soft Tissue Sarcoma
        Dr. Thara is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Agranulocytosis
        Dr. Thara is
        Experienced
        . Learn about Agranulocytosis.
        See more Agranulocytosis experts
      View All 107 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved